Beyond Genomics and GlaxoSmithKline Announce Partnership to Apply Systems Biology to Metabolic Diseases

BG Medicine, Inc.

Beyond Genomics and GlaxoSmithKline Announce Partnership to Apply Systems Biology to Metabolic Diseases

January 28, 2004

Waltham, Mass. and London, U.K. - January 28, 2004 - Beyond Genomics, Inc. (BG) and GlaxoSmithKline (GSK) announced today that they have entered into a research collaboration, option and license agreement in the area of systems biology for the purpose of drug discovery and development in metabolic diseases. This follows a successful pilot relationship between the companies that began in December 2002 and involved the use of BG's proprietary Systems Biology platform to elucidate disease pathways and identify biomarkers of disease state and drug response. Under the new agreement, GSK will pay BG an upfront fee and will fund the research program for its full term. BG is also eligible to receive additional payments and will retain certain rights to apply collaboration results in defined fields. Additional financial terms were not disclosed.

The new partnership will apply BG's Systems Biology technologies to GSK's ongoing study of disease and drug response in several metabolic disorders. The parties expect that the knowledge generated from the application of these new systems approaches will lead to a more complete understanding of metabolic disease pathways and drug mechanisms of action in animals and humans as well as improved clinical development strategies. Specifically, the companies anticipate that the collaboration will identify new biomarkers of disease and drug response with broad applicability to the drug discovery and development process.

"We are delighted to begin this important partnership with Beyond Genomics." said John Reardon, Senior Vice President of Discovery Research Biology at GSK. "Both parties have a shared vision and enthusiasm for the potential of Systems Biology to transform how new drugs are discovered and developed."

"We believe this agreement will enhance and further validates the value of Beyond Genomics' Systems Biology approach for pharmaceutical research and development," said Muz Mansuri, Executive Chairman of Beyond Genomics. "Since our founding in 2000, Beyond Genomics has been a pioneer in the emerging field of Systems Biology. This alliance with GSK, following the successful completion of our pilot agreement, represents a significant step forward in the evolution of BG as a commercial enterprise and partner to the pharmaceutical industry."

Systems Biology is the science of analyzing complex animal and/or human samples, and then measuring, integrating, comparing, and interpreting the results in an appropriate biologic context to elucidate knowledge about the biological processes Ð including drug response - under study. When applied to metabolic disorders, Systems Biology has the potential to uncover the molecular mechanisms of these related clinical syndromes, including common mechanisms, leading to better, faster, more cost-effective decisions in the discovery and development of drugs to treat one or more of these common disease states.

About GlaxoSmithKline

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For detailed company information, see (www.science.gsk.com).

About Beyond Genomics, Inc.

Founded in 2000, Beyond Genomics is an emerging biotechnology company that applies its proprietary Systems Biology platforms to develop novel therapeutics and biomarkers. Current approaches such as genomics and proteomics focus on one aspect of biological systems at a time. Rather than simplifying the inherent complexity of biological processes that underlie human diseases or that govern drug responses, Beyond Genomics has pioneered the creation of Molecular Phenotypesª to enable biological research at the systems level. Molecular Phenotypingª involves measuring complex biological samples, including simultaneously measuring transcripts, proteins and metabolites, and integrating these data sets with clinical information. Tracking changes in Molecular Phenotypesª can improve multiple aspects of pharmaceutical discovery and development, including drug safety and efficacy, drug response, and the etiology of disease. BG's Systems Biology platform integrates state-of-the-art technologies in proteomics, metabolomics, and bioinformatics. The company has also developed a proprietary BioSystematicsª data integration and knowledge management platform that generates connections, correlations, and relationships among thousands of measurable molecular components. Visit Beyond Genomics at (www.BeyondGenomics.com).